Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Viking Therapeutics (NASDAQ: VKTX) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's share price eroded by 24% in December, primarily on the back of a ...

The Motley Fool has positions in and recommends Merck. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.

Silence Therapeutics plc's Zerlasiran has done well, but Eli Lilly's Muvalaplin is simply better. Read more about SLN stock ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Keros Therapeutics (KROS – Research ...

TransCode’s common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Decembe TransCode Therapeutics (RNAZ) has entered into a securities purchase ...

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Werewolf Therapeutics (HOWL – Research Report) today and set a ...

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...